2023 - Research.com Medicine in Canada Leader Award
Randy D. Gascoyne mostly deals with Lymphoma, Diffuse large B-cell lymphoma, Pathology, Cancer research and Internal medicine. His Lymphoma study integrates concerns from other disciplines, such as Molecular biology and Survival analysis. His Diffuse large B-cell lymphoma research incorporates themes from Immunohistochemistry, Gene expression profiling and Rituximab.
His Pathology research integrates issues from Chromosomal translocation and Cytogenetics. Randy D. Gascoyne has included themes like Reed–Sternberg cell, Cyclin D2, Germinal center, Regulation of gene expression and STAT protein in his Cancer research study. His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine.
His scientific interests lie mostly in Lymphoma, Internal medicine, Diffuse large B-cell lymphoma, Cancer research and Pathology. His Lymphoma research is multidisciplinary, incorporating perspectives in Molecular biology, Cancer and Germinal center. Randy D. Gascoyne interconnects Gastroenterology, Surgery and Oncology in the investigation of issues within Internal medicine.
His Oncology research includes elements of Survival rate, Clinical trial, Survival analysis and ABVD. Randy D. Gascoyne has researched Diffuse large B-cell lymphoma in several fields, including CHOP, BCL6 and Gene expression profiling. In his study, which falls under the umbrella issue of Cancer research, Cyclin D1 is strongly linked to Mantle cell lymphoma.
Randy D. Gascoyne spends much of his time researching Lymphoma, Diffuse large B-cell lymphoma, Cancer research, Internal medicine and Oncology. The various areas that Randy D. Gascoyne examines in his Lymphoma study include Immunohistochemistry, BCL6, Gene, Somatic cell and Tumor microenvironment. His Diffuse large B-cell lymphoma research is included under the broader classification of Pathology.
His Cancer research research is multidisciplinary, relying on both Exome sequencing, Gene mutation, Mutation, Gene expression profiling and Germinal center. Internal medicine is frequently linked to Gastroenterology in his study. In his research, Venetoclax and Proportional hazards model is intimately related to International Prognostic Index, which falls under the overarching field of Oncology.
His primary areas of study are Lymphoma, Cancer research, Diffuse large B-cell lymphoma, Internal medicine and Gene. Randy D. Gascoyne mostly deals with International Prognostic Index in his studies of Lymphoma. His research in Cancer research intersects with topics in Exome sequencing, Gene mutation, Mutation, Cancer and Germinal center.
His Diffuse large B-cell lymphoma study combines topics from a wide range of disciplines, such as B-cell receptor, Molecular classification, Bruton's tyrosine kinase and Syk. His research integrates issues of Gastroenterology and Oncology in his study of Internal medicine. Randy D. Gascoyne combines subjects such as Molecular biology, Gene rearrangement and Fluorescence in situ hybridization with his study of BCL6.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Circos: An information aesthetic for comparative genomics
Martin I Krzywinski;Jacqueline E Schein;Inanc Birol;Joseph Connors.
Genome Research (2009)
Revised response criteria for malignant lymphoma
Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne.
Journal of Clinical Oncology (2007)
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
Andreas Rosenwald;George Wright;Wing C. Chan;Wing C. Chan;Joseph M. Connors.
The New England Journal of Medicine (2002)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans;Dennis D. Weisenburger;Timothy C. Greiner;Randy D. Gascoyne.
Stromal gene signatures in large-B-cell lymphomas
G Lenz;G Wright;S S Dave;W Xiao.
The New England Journal of Medicine (2008)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Morin Rd;Johnson Na;Severson Tm;Mungall Aj.
Nature Genetics (2010)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D Morin;María Méndez-Lago;Andrew J Mungall;Rodrigo Goya.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis;Vu N. Ngo;Georg Lenz;Pavel Tolar.
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave;George Wright;Bruce Tan;Andreas Rosenwald;Andreas Rosenwald.
The New England Journal of Medicine (2004)
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
Thomas M. Habermann;Edie A. Weller;Vicki A. Morrison;Randy D. Gascoyne.
Journal of Clinical Oncology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: